[Effect of a combined L-Dopa and decarboxylase inhibitor (Ro 4-4602) therapy in parkinsonism patients. Quantitative analysis of bradykinesia using reaction times].
D000368:Aged; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D003891:Desipramine / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004192:Discrimination, Psychological; D004357:Drug Synergism; D004576:Electromyography; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced / Q000175:diagnosis; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000601:surgery; D011930:Reaction Time; D013788:Thalamus / Q000601:surgery; D014282:Trihexyphenidyl / Q000627:therapeutic use
D010276:Parasympatholytics; D004295:Dihydroxyphenylalanine; D014282:Trihexyphenidyl; D002262:Carboxy-Lyases; D003891:Desipramine
Effekt einer kombinierten Behandlung von Parkinsompatienten mit l-Dopa und einem Decarboxylasehemmer (Ro 4-4602). Quantiative Analyse der Bradykinesie mittels Reaktionszeitmessungen.